NCT04204889View on ClinicalTrials.gov

Trial of Oxaloacetate in ALS

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

March 17, 2020

Primary Completion Date

August 2, 2023

Study Completion Date

August 2, 2023

Conditions
ALS
Interventions
DRUG

Oxaloacetic Acid

The first 3 patients will receive 500 mg twice daily, and subsequent cohorts will increase by 500 mg per dose to a maximum of 2500 mg twice daily.

Trial Locations (1)

66160

University of Kansas Medical Center, Kansas City

All Listed Sponsors
collaborator

Terra Biological LLC

INDUSTRY

lead

Omar Jawdat

OTHER

NCT04204889 - Trial of Oxaloacetate in ALS | Biotech Hunter | Biotech Hunter